Form 8-K - Current report:
SEC Accession No. 0001140361-25-013380
Filing Date
2025-04-11
Accepted
2025-04-11 08:53:01
Documents
14
Period of Report
2025-04-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20047282_8k.htm   iXBRL 8-K 41919
2 EXHIBIT 1.1 ef20047282_ex1-1.htm EX-1.1 71325
  Complete submission text file 0001140361-25-013380.txt   267891

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20250411.xsd EX-101.SCH 3997
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20250411_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20250411_pre.xml EX-101.PRE 16054
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20047282_8k_htm.xml XML 4071
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 25829980
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)